Cargando…

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial

OBJECTIVE: The aim of this study was to test the safety of diazoxide and to search for signs of efficacy in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In this multicenter, randomized, placebo-controlled, double-blind trial (treatment allocation was concealed), 102 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villoslada, Pablo, Rovira, Alex, Montalban, Xavier, Arroyo, Rafael, Paul, Friedemann, Meca-Lallana, Virginia, Ramo, Cristina, Fernandez, Oscar, Saiz, Albert, Garcia-Merino, Antonio, Ramió-Torrentà, Lluís, Casanova, Bonaventura, Oreja-Guevara, Celia, Muñoz, Delicias, Martinez-Rodriguez, Jose Enrique, Lensch, Eckart, Prieto, Jose Maria, Meuth, Sven G., Nuñez, Xavier, Campás, Clara, Pugliese, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567455/ https://www.ncbi.nlm.nih.gov/pubmed/26405686 http://dx.doi.org/10.1212/NXI.0000000000000147

Ejemplares similares

Cognitive Dysfunctions and Assessments in Multiple Sclerosis
por: Oreja-Guevara, Celia, et al.
Publicado: (2019)

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
por: Sepúlveda, Maria, et al.
Publicado: (2016)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
por: Meca-Lallana, J. E., et al.
Publicado: (2021)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
por: Fernández, Óscar, et al.
Publicado: (2023)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
por: Fernández, Óscar, et al.
Publicado: (2023)

Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling
por: Valverde, Sergi, et al.
Publicado: (2015)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Evaluating the effect of multiple sclerosis lesions on automatic brain structure segmentation
por: González-Villà, Sandra, et al.
Publicado: (2017)

One-shot domain adaptation in multiple sclerosis lesion segmentation using convolutional neural networks
por: Valverde, Sergi, et al.
Publicado: (2018)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Clinical and radiological features of cerebral amyloid angiopathy-related inflammation
por: Bravo, Gary Álvarez, et al.
Publicado: (2021)

Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Gascón-Giménez, Francisco, et al.
Publicado: (2023)

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives
por: Bravo, Gary Álvarez, et al.
Publicado: (2022)

An expert patient program to improve the empowerment and quality of life of people with multiple sclerosis: protocol for a multicenter pre-post intervention study
por: Robles-Sanchez, Miguel Angel, et al.
Publicado: (2023)

Clinical heterogeneity in patients with myoclonus associated to COVID-19
por: Álvarez Bravo, Gary, et al.
Publicado: (2022)

Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat(®) Methodology
por: Fernandez, Oscar, et al.
Publicado: (2021)

Disease-related knowledge measurement instruments of people affected by multiple sclerosis: protocol for a systematic psychometric review
por: Gonzalez-del-Rio, Marina, et al.
Publicado: (2021)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Anti-NMDA receptor encephalitis secondary to SARS-CoV-2 infection
por: Alvarez Bravo, G., et al.
Publicado: (2020)

Encefalitis anti-NMDA-R secundaria a infección por SARS-CoV-2
por: Álvarez Bravo, G., et al.
Publicado: (2020)

Effects of diazoxide in experimental acute necrotizing pancreatitis
por: de Oliveira Andrade, Roberta, et al.
Publicado: (2017)

Stability of Diazoxide in Extemporaneously Compounded Oral Suspensions
por: Friciu, Mihaela, et al.
Publicado: (2016)

The danger of diazoxide in the neonatal intensive care unit
por: Desai, Jay, et al.
Publicado: (2021)

Diazoxide for Neonatal Hyperinsulinemic Hypoglycemia and Pulmonary Hypertension
por: Newman-Lindsay, Shoshana, et al.
Publicado: (2022)

Paraneoplastic Limbic Encephalitis in a Male with Squamous Cell Carcinoma of the Lung
por: Sauri, Tamara, et al.
Publicado: (2015)

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells
por: Gil-Varea, Elia, et al.
Publicado: (2020)

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis
por: Muñoz-San Martín, María, et al.
Publicado: (2022)

Diazoxide Promotes Oligodendrocyte Precursor Cell Proliferation and Myelination
por: Fogal, Birgit, et al.
Publicado: (2010)

Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
por: Hole, Lisa Drange, et al.
Publicado: (2014)

Diazoxide preconditioning antagonizes cytotoxicity induced by epileptic seizures★
por: Fu, Qingxi, et al.
Publicado: (2013)

Prevalence and safety of diazoxide in the neonatal intensive care unit
por: Gray, Keyaria D, et al.
Publicado: (2018)

Diazoxide for Lowering Insulin Levels in Breast Cancer Patients
por: Fink, Michael K., et al.
Publicado: (2017)

Successful medical management of insulinoma with diazoxide for 27 years
por: Warren, Annabelle M, et al.
Publicado: (2020)

Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
por: Sotiridou, Ellada, et al.
Publicado: (2021)

Diazoxide-Induced Hypertrichosis in a Neonate With Transient Hyperinsulinism
por: Boskabadi, Seyyed Javad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bdooi35qmdr9jhqkbcot5ni2n7